Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback